2024
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Kahn S, Deanfield J, Jeppesen O, Emerson S, Boesgaard T, Colhoun H, Kushner R, Lingvay I, Burguera B, Gajos G, Horn D, Hramiak I, Jastreboff A, Kokkinos A, Maeng M, Matos A, Tinahones F, Lincoff A, Ryan D, Investigators S. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care 2024, 47: 1350-1359. PMID: 38907683, PMCID: PMC11282386, DOI: 10.2337/dc24-0491.Peer-Reviewed Original ResearchCardiovascular diseaseMagnitude of weight reductionDouble-blind trialEffect of semaglutideCases of diabetesSubcutaneous semaglutideTreatment armsFollow-upSemaglutideDiabetesHbA1cObesityIntervention exposureGlycemiaPlaceboWeeksBody weightGlycemic outcomesDiseaseWeight reductionNormoglycemiaTrialsParticipantsProgressionKg/m2
2023
Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Kelly A, Arslanian S, Hesse D, Iversen A, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff A. Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity 2023, 31: 2139-2149. PMID: 37196421, DOI: 10.1002/oby.23808.Peer-Reviewed Original ResearchConceptsWeekly subcutaneous semaglutideBMI categoriesSubcutaneous semaglutideWeek 68Glucagon-like peptide-1 receptor agonistsObesity thresholdPeptide-1 receptor agonistsHigh-intensity physical activityObesity class IIIOverweight BMI categoryLogistic regression modelsOverweight BMIReceiving placeboTeens trialLifestyle interventionReceptor agonistPhysical activityPlaceboBMISemaglutideParticipants' BMIClass IIIOverall populationPhase 3aHealthy nutrition